a2AP antibody | knockout validation | Molecular Innovations MAP4H9
DOI
//dx.doi.org/10.13070/ko.en.7.2214
Date
2017-03-18

This is a knockout-validated antibody summary, based on the publication "Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG3,kappa

Company: Molecular Innovations

Antibody: a2AP

Catalog number: MAP4H9

Summary: Mouse monoclonal IgG3,kappa against full length native mouse antiplasmin. Reacts with mouse by western blot, ELISA, and function inhibition.

Validation Method

Western blot

Sample

a2AP+/+ and a2AP-/- mice thrombi.

Blocking agent

1% BSA.

Primary incubation

Membrane was incubated with pooled monoclonal antibodies specific for mouse a2AP (monoclonal antibodies 173, 766 as well as 4h9, 27c9; 5 ug/ml; Molecular Innovations, Inc. MI.).

Secondary incubation

Secondary goat anti-mouse antibody IRDye 800CW.

Detection

Infrared imager (LI-COR ODYSSEY).

Figure

Please see Figure 1g in the article [1].

References
  1. Reed G, Houng A, Wang D. Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin. Arterioscler Thromb Vasc Biol. 2014;34:2586-93 pubmed publisher